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Abstract 
Background: Betaine (BET), a component of many foods, is an essential osmolyte and a source of methyl groups; 
it also shows an antioxidant activity. Moreover, BET stimulates muscle differentiation via insulin like growth factor I 
(IGF-I). The processes of myogenesis and osteogenesis involve common mechanisms with skeletal muscle cells and 
osteoblasts sharing the same precursor. Therefore, we have hypothesized that BET might be effective on osteoblast 
cell differentiation.
Methods: The effect of BET was tested in human osteoblasts (hObs) derived from trabecular bone samples obtained 
from waste material of orthopedic surgery. Cells were treated with 10 mM BET at 5, 15, 60 min and 3, 6 and 24 h. The 
possible effects of BET on hObs differentiation were evaluated by real time PCR, western blot and immunofluores-
cence analysis. Calcium imaging was used to monitor intracellular calcium changes.
Results: Real time PCR results showed that BET stimulated significantly the expression of RUNX2, osterix, bone sialo-
protein and osteopontin. Western blot and immunofluorescence confirmed BET stimulation of osteopontin protein 
synthesis. BET stimulated ERK signaling, key pathway involved in osteoblastogenesis and calcium signaling. BET 
induced a rise of intracellular calcium by means of the calcium ions influx from the extracellular milieu through the 
L-type calcium channels and CaMKII signaling activation. A significant rise in IGF-I mRNA at 3 and 6 h and a significant 
increase of IGF-I protein at 6 and 24 h after BET stimulus was detected. Furthermore, BET was able to increase signifi-
cantly both SOD2 gene expression and protein content.
Conclusions: Our study showed that three signaling pathways, i.e. cytosolic calcium influx, ERK activation and IGF-I 
production, are enhanced by BET in human osteoblasts. These pathways could have synergistic effects on osteo-
genic gene expression and protein synthesis, thus potentially leading to enhanced bone formation. Taken together, 
these results suggest that BET could be a promising nutraceutical therapeutic agent in the strategy to counteract the 
concomitant and interacting impact of sarcopenia and osteoporosis, i.e. the major determinants of senile frailty and 
related mortality.
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Background
Betaine (BET) is an important human nutrient [1], origi-
nally identified during the extraction of sucrose from 
sugar beets (Beta vulgaris). It was then found that BET is 
widely distributed in many marine invertebrates, plants, 
and animals. BET physiologically functions as either an 
organic osmolyte to protect cells under stress or as a 
methyl donor via trans-methylation [2]. Extensive in vitro 
and in  vivo studies suggested that dietary BET supple-
mentation was effective in reducing body fat deposition, 
improving hepatic steatosis [3], and in increasing lean 
mass gains [4]. Several investigations reported in fact sig-
nificant effects of BET on sports performance and body 
composition [3–5]. However, the mechanisms underlying 
these effects have not been defined yet.
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As recently reviewed [4], BET favours lipolysis and 
inhibits lipogenesis via gene and protein expression; it 
promotes the autocrine/endocrine release of insulin-
like growth factor type I (IGF-I), and modulates its rela-
tive receptor signaling pathway. In particular, it has been 
shown that BET enhances neo myotubes formation and 
differentiation while promoting IGF-I gene and protein 
expressions in C2C12 murine myoblasts [6], a model of 
skeletal muscle development [7]. IGF-I has long been 
known to play a role not only in muscle hypertrophy but 
even in bone strength [8, 9]. In bone, IGF-I stimulates 
osteoblast differentiation and bone formation through 
the activation of the mammalian target of rapamycin 
(mTOR) pathway [10]. Indeed, IGF-I stimulates RUNX2 
downstream gene expression, a critical step in osteogen-
esis, by up-regulating the protein levels of PI3K subunits, 
Akt, and increasing p70S6 kinase (p70 S6K) thus stimu-
lating osteoblast differentiation, protein synthesis and 
cell growth [11]. The critical role of IGF-I in bone is fur-
ther supported by the inhibition of osteoblast differentia-
tion, protein synthesis and cell growth after treating the 
cells with antibodies against IGF-I [9–11].
Skeletal muscle and bone are of mesodermal origin 
and osteogenesis and myogenesis process are character-
ized by a close interaction and several common molecu-
lar mechanisms [12–14]. Moreover, numerous factors 
enhance both myogenic and osteogenic differentiation, 
including IGF-I and calcium. IGF-I has long been known 
to play a role in muscle hypertrophy and bone strength. 
Based on this evidence and on our encouraging results 
obtained treating myostasts with BET, we have hypoth-
esized that BET might stimulate the differentiation of 
bone cells [6]. Osteoblast differentiation [15] is a multi-
step process, where mesenchymal cells differentiate along 
the osteoblast lineage until the osteocyte state. RUNX2 
is the main transcription factors inducing the osteogenic 
process [16] by activating other important osteoblast-
specific transcription factors, like osterix (OSX) [17, 18]. 
During the differentiation of pre-osteoblasts into mature 
osteoblasts, RUNX2-OSX axis regulates the expres-
sion of bone marker proteins, including type I collagen, 
bone sialoprotein (BSP) and osteopontin (OPN) [15, 16, 
19]. The effects of RUNX2 in bone development is posi-
tively regulated by ERKs cascade. In fact, differentiation 
of human marrow stromal cells to osteoblasts is associ-
ated to ERK1/2 phosphorylation while the inhibition of 
both ERK1 and ERK2 activities by the dominant negative 
ERK1 protein prevents differentiation of human osteo-
blasts [20] and shifts human marrow stromal cells to adi-
pogenesis [21].
Based upon these considerations, we have investigated 
if BET could induce osteoblast differentiation by evaluat-
ing the expression of osteogenic genes, i.e. RUNX2, OSX, 
BSP and OPN, and if it could activate important intracel-
lular pathway such as ERK pathway, protein synthesis and 
calcium signaling, which are fundamental for the recruit-
ment and function of bone cells [22]. In this preliminary 
evaluation of the pathways involved in the potential 
osteogenic effect of BET, we extended our investigation 
on the potential anti-oxidative effect of BET [23]. Since 
Superoxide Dismutase 2 (SOD2), a crucial mitochon-
drial enzyme playing a role in antioxidant activity [24], is 
associated to intracellular calcium perturbations [25], we 
have evaluated SOD2 gene expression in human osteo-
blasts after BET treatment.
The present study could provide new insights on the 
potential function of BET as a nutraceutical supplemen-
tation in the strategy to counteract the concomitant and 
interacting impact of sarcopenia and osteoporosis, i.e. 
the major determinants of senile frailty and related mor-
tality [26].
Methods
Materials
Fura-2 acetoxymethyl ester (Fura-2/AM) was from Cal-
biochem (La Jolla, CA, USA). Bis-(1,3-dibutylbarbitu-
ric acid) trimethine oxonol,  DiBAC4-(3), was obtained 
from molecular probes (Eugene, OR, USA). All reagents, 
including materials for video imaging experiments, were 
purchased from Sigma Chemical Co. (St. Louis-MO, 
USA).
Primary antibodies against: Calnexin (H-70), GAPDH 
(FL-335), CaMKII (M-176), pCaMKII (Thr286), p70 
S6 (C-18), pp70 S6 (C-18), ERK1 (K-23), ERK2 (C-14), 
pERK1/2 (E-4), OPN (K-20), peroxidase-conjugated sec-
ondary antibodies for western blot analysis and FITC or 
Rhodamine-conjugated antibodies for immunofluores-
cence study were purchased from Santa Cruz Biotechnol-
ogy (Heidelberg, Germany).  AlexaFluor®488-Phalloidin 
was obtained from Life Technologies (Carlsbad-CA, 
USA).
Human osteoblast‑like cells (hOBs) cultures
Human bone cell cultures were established by means of 
a modified version of the Gehron-Robey and Termine 
procedure [27] using trabecular bone samples obtained 
from waste material of female patients during orthope-
dic surgery for degenerative diseases or traumatic frac-
tures of the femoral neck requiring osteotomy. None of 
the patients (aged 71–82  year) had any malignant bone 
diseases and all of them gave their written consent for 
the use of the waste material. The protocol was approved 
by the Institutional Ethical Committee (Protocol BMU-
WNT, 25.03.2008; amendment 1, 29.9.2012). No signifi-
cant trend related to donor age was observed in any of 
the effects studied. Briefly, the trabecular bone was cut 
Page 3 of 14Villa et al. J Transl Med  (2017) 15:132 
into small pieces and thoroughly washed with commer-
cial standardized Joklik’s modified MEM serum-free 
medium, to remove no adherent marrow cells. The pieces 
were incubated with rotation at 37 °C for 30 min with the 
same medium containing 0.5 mg/ml type IV collagenase, 
and collagenase digestion was stopped by the addition of 
Iscove’s modified medium containing 10% fetal bovine 
serum (FBS). Between eight and ten pieces from each 
patient were then placed in 25 cm2 flasks and cultured in 
IMDM containing 10% FBS, 100 U/ml penicillin, 100 µg/
ml streptomycin, 50  U/ml mycostatin, and 0.25  µg/ml 
amphotericin B until confluence; the culture medium was 
changed every 2–3 days. The cell population was tested 
for alkaline phosphatase (ALP) and osteocalcin (BGP) 
production after 1,25(OH)2D3  10−8 M to ensure that the 
cells were endowed with osteoblast characteristics. ALP 
and BGP were measured by means of a multianalyzer 
COBAS (Roche Diagnostics SpA, Monza, Italy). Cells 
were used at first passage to reduce the possibility of phe-
notype changes.
Reverse transcription and semi‑quantitative real time PCR
After 24  h of serum starvation, confluent hObs were 
treated with BET (10 mM) for 1, 3, 6 and 24 h. The rela-
tive expression of osteogenic genes RUNX2, OSX, BSP, 
OPN was evaluated. IGF-I and SOD2 mRNA levels were 
also evaluated. Total RNA from confluent hOBs was 
extracted using TRIzol reagent (Thermo Fisher Scien-
tific Inc., Waltham, MA USA), according to the manu-
facturer’s instructions. 1  µg of total RNA was reverse 
transcribed to cDNA using oligodT primers and M-MLV 
reverse transcriptase (Promega Corporation, Madison, 
WI, USA). 10  µg of cDNA were subjected to real-time 
PCR reactions using primer-probe sets validated and 
purchased as “Assay-on-Demand” from Applied Biosys-
tems (Thermo Fisher Scientific Inc., Waltham, MA USA) 
in singleplex PCR mix. Real time PCR reaction was per-
formed in an ABI  PRISM® 7900 Sequence Detection Sys-
tem (Thermo Fisher Scientific Inc., Waltham, MA USA). 
Each gene expression was first normalized with β-actin 
content and the relative quantification treated/untreated 
was calculated with the  2−ΔΔCt method. Three replicates 
were performed for each experimental point and experi-
ments were repeated several times with cells obtained 
from different donors.
Western blot analysis
After 24  h of serum starvation, confluent hObs were 
treated with BET (10  mM) for 5, 15 and 60  min or for 
longer time (6–24  h). At the end of the experiments, 
hOBs cells were homogenized in RIPA lysis buffer sup-
plement with protease inhibitors as described [28]. Ali-
quots of 35  μg supernatant proteins, quantified using 
Bradford method, were resolved by SDS-PAGE. Elec-
trophoresed proteins were transferred to nitrocellulose 
membrane  (Protran®,  Whatman® Schleicher & Schuell, 
Sigma Chemical Co., St. Louis-MO, USA). The mem-
branes were incubated with specific primary antibod-
ies and then with HRP conjugated anti species-specific 
secondary antibodies. The protein signals were normal-
ized using the relevant calnexin or anti GAPDH bands. 
Immunoreactive bands were visualized by an enhanced 
chemiluminescence method (Amersham Pharmacia Bio-
tech, Piscataway, NJ, USA). Bands on X-ray films were 
then quantified using Scion Image software (Scion Corp., 
Frederick, MD, USA). The data were then converted to 
fold change (FC) of the control.
Immunofluorescence analysis
After 24  h of serum starvation, hObs were treated for 
3, 6 and 24  h with BET (10  mM). hObs cells, fixed and 
permeabilized as previously described [28], were blocked 
with PBS containing 1% bovine serum albumin. Cells 
were then immunostained with specific antibodies FITC 
or rhodamine conjugated and nuclei-revealed with DAPI 
staining. Slides were mounted with Moviol. Cells were 
observed using Nikon Eclipse 50I microscopy and images 
were captured using Nis-Elements D 4.00 software 
(Nikon Instruments Europe BV, Netherlands). Data were 
displayed and analyzed using Adobe Photoshop CS4. 
Automated quantification on immunofluorescence signal 
was performed by using Image J program (http://imagej.
nih.gov/ij/) [29].
Intracellular calcium determination at a single cell level
BET possible action on the intracellular calcium con-
centration  ([Ca2+]i) was studied in two different experi-
mental condition: a physiological extracellular calcium 
concentration  ([Ca2+]o = 2 mM) and a nominally extra-
cellular calcium free condition. In the first condition all 
the experiments have been performed in Krebs–Ringer-
HEPES solution (KRH, NaCl 125  mM, KCl 5  mM, 
 KH2PO4 1.2 mM,  MgSO4 1.2 mM,  CaCl2 2 mM, glucose 
6  mM and HEPES 25  mM, pH 7.4). Nominally calcium 
free condition consisted in a KRH lacking of  CaCl2, with-
out calcium chelators to avoid cytotoxic effects [30]. Pos-
sible calcium ions residues derived by the doubly distilled 
water. After 24 h serum starvation, cells, seeded on a glass 
coverslip (24  mm diameter, thickness 0.13–0.17  mm, 
VWR International, West Chester, Pennsylvania, USA), 
were incubated for 20 min at 37 °C with 2.5 µM Fura-2/
AM acetoxymethyl ester (Fura-2/AM) and 2.5  µM Plu-
ronic F-127 in 1 ml KRH. At the end of Fura-2/AM load-
ing, the glass coverslips were placed on a thermostated 
(TC-202 A) PDMI-2 perfusion chamber (Medical Sys-
tem Corporation, Harvard Apparatus, Holliston, MA, 
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USA), positioned on a microscope stage (TE 200, Nikon, 
Tokyo, Japan) connected to a CCD intensified camera 
(Extended Isis, Photonic Science, Millham, UK). The 
intracellular calcium concentration in single cells was 
continuously monitored using the fluorescence image 
acquisition and data analysis system supplied by applied 
imaging (High Speed Dynamic Video Imaging Systems, 
Quanticell 700, Sunderland, UK). The intracellular free 
calcium concentration,  [Ca2+]i, was derived from a cali-
bration performed with external standards of calcium 
and Fura-2/AM applied to the 340/380 nm images [31]. 
BET was administered to cells in a single dose of 10 mM. 
The single-cell analysis provided the following results: (i) 
the percentage of responsive cells, considering only cells 
which responded to BET administration with  [Ca2+]i 
increments equal or above 20 nM; (ii) the mean  [Ca2+]i 
rise, derived from the subtraction of the baseline value to 
the peak value after BET administration for each cell and 
then averaged for all the analyzed cells.
Experiments with promoters and/or inhibitors of  [Ca2+]i 
rise
To study  [Ca2+]i changes in nominally calcium free con-
ditions, 10 µM Thapsigargin from a DMSO stock solution 
was used before and after BET administration. Thapsi-
gargin is a specific endoplasmic calcium pump inhibitor, 
which induces an immediate release of the stored intra-
cellular calcium. In order to determine BET effect on 
calcium entry from the extracellular buffer, agonists and 
antagonists of cellular membrane calcium channels were 
used in physiological condition. Bay-K 8644, a known 
L-type  Ca2+ channels (VDCCL) agonist, was solubilized 
in DMSO and administered to hOBs at 400 nM concen-
tration. The dihydropyridine derivatives Nimodipine 
and Nifedipine, two known antagonists of VDCCL [32], 
were solubilized in DMSO and were administered to 
cells (30  µM) 10 min before BET administration.  LaCl3, 
known to block the cell membrane  Ca2+ channels in an 
irreversible manner and prevent any  Ca2+ movement 
across the membrane [33, 34], was used at 250 µM con-
centration 5 min before BET administration.  MnCl2 was 
used to evaluate calcium entry from the extracellular 
medium due to its ability of quenching the fluorescence 
emission at 360 nm, the wavelength at which the excita-
tion of Fura-2/AM is independent from the presence of 
calcium [35].
Measurement of membrane potential
The measurement of the membrane potential before and 
after stimulus was undertaken by using  DiBAC4-(3), a 
lipophilic, negatively charged slow potential-sensitive 
oxonol dye [36], which responds to membrane depolari-
zation moving from the extracellular medium into the 
cytosol. The increased intracellular concentration of the 
dye results in an increase of the fluorescence emission 
[37]. Cells were loaded with 500 nM  DiBAC4-(3) in KRH 
solution and incubated for 15 min at 37 °C under 300 rpm 
shaking in a Thermomixer (Eppendorf s.r.l. Milan, Italy). 
At the end of incubation, fluorescence was recorded (λex 
490, λem 510) and defined as “Before stimulus”. Then, cells 
were treated with 10  mM BET, 1  µM Gramicidin or a 
Hyperpolarizing KRH solution (0 mM NaCl, 5 mM KCl). 
Fluorescence was immediately recorded in the case of 
BET and Hyperpolarizing KRH solution and after 5 min 
in the case of Gramicidin. In all these samples, fluores-
cence was defined as “After stimulus”.
Statistical analysis
Data are presented as the mean ± SD of experiments per-
formed three–nine. Statistical analysis were performed 
with specific statistical packages (Prism v 7.00 GraphPad 
Software, San Diego, CA, USA and SPSS 20 statistical 
software, Chicago, IL, USA). Statistically significant dif-
ferences were determined using t student test, ANOVA 
tests (nonparametric ANOVA test-Kruskal–Wallis 
test) followed by appropriate multiple-comparison test: 
Dunn’s post test, differences were considered significant 
when p ≤ 0.05.
Results
Betaine effects on osteogenic gene and protein expression 
in human osteoblasts
Cell culture responded to 24  h 1,25(OH)2D3  (10−8 M) 
treatment with a significant increase of ALP and BGP, 
assuring that the cultures were endowed with osteo-
blastic characteristics. Basal and stimulated ALP activ-
ity was respectively 47.20 ± 10.68 and 69.91 ± 12.72 UI/
mg protein (p < 0.001), and BGP values were 8.43 ± 0.98 
and 27.63 ± 2.99 ng/mg protein (p < 0.001). To investi-
gate the role of BET on osteoblast differentiation, hOBs 
were cultured with 10 mM BET for 1, 3, 6 and 24 h. We 
firstly investigated BET action on crucial osteoblastic 
transcription factors: RUNX2 and OSX [15–19]. The real 
time PCR analysis showed that RUNX2 and OSX mRNAs 
expression was significantly increased after 1 h (p < 0.05; 
p  <  0.001) and 3  h (p  <  0.001; p  <  0.001; Fig.  1a), OSX 
gene expression was significantly enhanced not only at 
1 and 3  h but also after 6  h (p  <  0.05, Fig.  1a). Because 
the expression of many osteogenic proteins, including 
OPN and BSP, is directly controlled by RUNX2-OSX 
axis [18, 19], we determined BSP and OPN expres-
sion levels: BSP and OPN mRNA expressions increased 
significantly after 3  h of BET treatment (p  <  0.001) and 
the increase of OPN mRNA lasted until 6  h (p  <  0.01 
Fig.  1a). After 24  h, all gene expression levels returned 
to control level (Fig. 1a). We also evaluated OPN protein 
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levels. Immunofluorescence (IF) and western blot analy-
ses revealed an increase of OPN protein level after 6 and 
24 h (p < 0.05) of treatment (Fig. 1b, c).
Intracellular pathways activated by Betaine: Betaine 
stimulates ERKs and IGF‑I pathways
To further elucidate the osteogenic effect of BET, we eval-
uated ERKs activation. Western blot results showed that 
BET (10 mM) increased significantly the phosphorylation 
of ERK1 (p < 0.001) and ERK2 (p < 0.001) after 15 min as 
shown by the ratio between their phosphorylated and not 
phosphorylated forms (Fig. 2a). BET (10 mM) also signifi-
cantly stimulated one of the major activator of ERK, IGF-
I. The gene expression of IGF-I increased significantly 
after 3 and 6 h (p < 0.001; Fig. 2b) and returned to con-
trol level after 24 h, whereas IGF-I receptor mRNA lev-
els were not affected by BET treatment (data not shown). 
Accordingly, immunofluorescence for IGF-I showed an 
increase in IGF-I-positive cells after 6 h (p < 0.001) and 
24 h (p < 0.05; Fig. 2c). BET was also able to stimulate the 
activation levels of p70 S6 kinase after 15 min (p < 0.001; 
Fig. 2d).
Intracellular pathways activated by Betaine: Betaine 
induces calcium influx
Since ERKs signaling can be modulated by calcium sign-
aling, a key parameter for the regulation of osteoblastic 
differentiation [22, 38, 39], we analyzed the effect of BET 
on calcium fluxes. The administration of 10 mM BET to 
hOBs in nominally calcium free condition did not induce 
any cytosolic calcium rise. The subsequent administration 
of Thapsigargin, a drug able to empty the calcium stores 
from the cytosolic endoplasmic reticulum, resulted in an 
increase of  [Ca2+]i, thus demonstrating the full viability 
of the cells as well as the integrity of their calcium stores 
(Fig.  3a, Table). The administration of BET (10  mM) 
in presence of 2  mM  [Ca2+]o, caused a  [Ca2+]i rise in 
40.8 ± 28.0% of the analyzed cells (Fig. 3b, Table), suggest-
ing a role of BET in inducing a calcium influx into hOBs 
from the extracellular milieu. The next step was to explore 
BET mechanism inducing calcium influx into hOBs. At 
first, the possible involvement of L-type calcium channels 
(VDCCL) was considered. These channels are known to 
be differently expressed during hOBs differentiation [40, 
41] and their functionality is modulated by 1,25(OH)2 
vitamin D3 [42]. When an agonist of VDCCL, Bay-K 8644 
was added to hOBs, an increase of  [Ca2+]i was recorded 
indicating the presence of active VDCCL in hOBs. The 
same cells, stimulated with BET after a wash and restora-
tion of initial experimental conditions, failed to respond 
with an increase in the  [Ca2+]i (Fig. 3c, Table). Similarly, 
when BET was first administered to hOBs, Bay-K 8644 did 
not produce any  [Ca2+]i increase (Fig.  3d, Table). These 
observations lead to the conclusion that BET induces cal-
cium influx from the same VDCCL activated by Bay-K 
8644. Another demonstration of VDCCL involvement 
came from the use of Nimodipine and Nifedipine, known 
inhibitors of these channels. Unexpectedly, the adminis-
tration of both inhibitors in hOBs produced a slow and 
slight increase in the  [Ca2+]i with a plateau after 400 s. The 
possible  [Ca2+]i increase following these inhibitors was 
described before in SaOS-2 cells [43]. After the inhibition 
of VDCCL by Nimodipine and Nifedipine, BET addition 
did not exert any  [Ca2+]i change (Fig.  3e, Table). Since 
both agonist (Bay-K 8644) and antagonists (Nimodipine 
and Nifedipine) abolished BET effect on hOBs, it is con-
ceivable that BET determines a calcium influx acting on 
the L-type calcium channels. To better understand the 
origin of BET-induced calcium influx,  LaCl3, an inorganic 
inhibitor of calcium entry [34], was pre administered to 
(See figure on next page.) 
Fig. 2 Betaine activates ERKs pathway and IGF-I gene and protein expression. a Representative western blot and relevant quantification of ERK 
pathway activation: in hObs treated with 10 mM BET, ERK1/2 activation peak was observed at 15 min. b 10 mM BET increased significantly IGF-I 
gene expression respect to control (CONTR) at 3 and 6 h, as measured by real time PCR. c Immunofluorescence study and relevant quantification 
showed an increase in the number of IGF-I positive cells in BET condition at 6 and 24 h (magnification: 20×). d Representative western blot and rel-
evant quantification: after 15 min, BET induced a significant activation of p70 S6 kinase. Data are the mean ± SD of six experiments performed with 
cells obtained from different donors. ANOVA for non parametric data (Kruskal–Wallis) with Dunn’s multiple comparison test: ***p ≤ 0.001 vs control. 
For western blot-immunofluorescence studies, Student’s t test: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
(See figure on previous page.) 
Fig. 1 Effects of Betaine on osteogenic gene and protein expression in human osteoblasts. a Real time PCR assay: 10 mM BET stimulated signifi-
cantly, compared to control (CONTR), the gene expression of RUNX2 at 1 and 3 h, of OSX at 1, 3 and 6 h, of BSP at 3 h and of OPN at 3 and 6 h. b 
Immunofluorescence staining of OPN protein after 6 h of 10 mM BET treatment and relevant quantification showing an increase in OPN protein 
compared to control (CONTR). Osteoblastic morphology was analyzed by Phalloidin (red) and OPN (green) staining (magnification: 20×). c Repre-
sentative western blot and relevant quantification of OPN protein content increased after 24 h of 10 mM BET treatment. Data are the mean ± SD of 
six to nine experiments performed with cells obtained from different donors. ANOVA for non parametric data (Kruskal–Wallis) with Dunn’s multiple 
comparison test: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 vs control (CONTR). For western blot-immunofluorescence studies, Student’s t test: *p ≤ 0.05
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Statistical analysis of the effect on [Ca² ]ᵢ exerted by Betaine administration
[Ca² sllecdezylanAₒ]
(n)
% Responsive 
cells
(mean ± SD)
Δ[Ca² ]ᵢ (nM)
(mean ± SD)
0 mM 136 0 0
2 mM 128 40.8 ± 28.0 30.2 ± 9.0
2 mM after Bay-K 8644 53 0 0
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after Nifedipine 72 0 0
after LaCl 43 14.5 ± 8.0 30.4 ± 1.0
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BET treated hOBs, a reduction of  [Ca2+]i was observed 
(Fig. 3f, Table). The final confirmation of a calcium influx 
from the extracellular buffer induced by BET came from 
the quenching of Fura-2/AM fluorescence, using 2  mM 
 MnCl2.  Mn2+ ions are able to pass the cell membrane 
through the same channels involved in the  Ca2+ entry. 
Once inside the cells,  Mn2+ ions bind to Fura-2/AM and 
their presence is recorded by the fluorescence emission 
quenching due to the excitation at 360  nm, the wave-
length at which the excitation of Fura-2/AM is independ-
ent from the presence of calcium [35]. When  MnCl2 was 
added to hOBs 10 s after BET, a reduction of Fura-2/AM 
fluorescence due to an influx of  Mn2+ ions was recorded 
(Fig. 3h).
Betaine depolarizes hObs membrane
Since VDCCL are defined as voltage-operated calcium 
channels, a possible direct effect of BET on membrane 
depolarization was considered. The cell membrane 
potential was measured by the use of  DiBAC4-(3), a 
fluorescent probe whose fluorescence intensity increases 
in depolarized conditions while decreases in hyperpolar-
izing conditions. The hObs basal membrane potential 
was considered as “Before stimulus” and indicated as 
100%. The addition of 10 mM BET increased by 18% the 
fluorescence intensity, indicating a depolarizing effect, 
as what recorded with Gramicidin (plus 23%), a known 
depolarizing agent, and opposite to what recorded 
(minus 19%) with KRH Hyperpolarizing buffer (Fig. 4).
Betaine enhances CaMKII signaling pathway
Since BET increased  [Ca2+]i through VDCCL channels, 
the possible effect of 10  mM BET on  Ca2+/calmodulin-
dependent kinase II (CaMKII) was evaluated. BET sig-
nificantly increased CaMKII positive cells number 
(p < 0.05) after 24 h of stimuli, as shown by immunofluo-
rescence analysis (Fig. 5a). Moreover, several works have 
demonstrated that CaMKII isoform plays a critical role 
in osteoblastic differentiation regulating the activation of 
many transcription factors including OSX [39, 44]. BET 
(See figure on previous page.) 
Fig. 3 Betaine induces calcium influx from the extracellular milieu. a 10 mM Betaine in nominally free  [Ca2+]o, followed by 10 µM Thapsigargin. b 
10 mM Betaine in 2 mM  [Ca2+]o. c 400 nM Bay-K 8644, wash and restoration of the initial condition (time break axis), followed by 10 mM Betaine 
in 2 mM  [Ca2+]o. d 10 mM Betaine followed by 400 nM Bay-K 8644 in 2 mM  [Ca
2+]o. e 10 min incubation (time break axis) with 30 µM Nimodipine, 
followed by 10 mM BET administration (2 mM  [Ca2+]o). f 30 µM Nifedipine incubation for 10 min (time break axis) and subsequent treatment with 
10 mM BET (2 mM  [Ca2+]o). g Administration of 250 µM  LaCl3 and 5 min incubation (time break axis), followed by 10 mM BET (2 mM  [Ca
2+]o). h 
Fluorescence intensity changes of Fura-2/AM recorded at the calcium insensitive excitation wavelength of 360 nm (λem = 510 nm), after the admin-
istration of 2 mM  MnCl2 in presence of 10 mM BET (2 mM  [Ca
2+]o). These results lead to the hypothesis that BET induced calcium influx through 
L-type voltage-dependent  Ca2+ channels. All the stimuli were added at the time points indicated by the arrows in the graphs. Each graph shows the 
intracellular calcium changes of a cells representative group from at least 3–6 independent experiments. Each line in the graphs display a single cell 
behavior. The table reported in the graph summarizes the number of analyzed cells together with the percentage of responsiveness and the mean 
 [Ca2+]i increases for all the experiments here described
* * *
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Fig. 4 Betaine evokes hOBs membrane depolarization.  DiBAC4-(3) (500 nM) in KRH solution (2 mM  CaCl2) assay: BET induced membrane depolari-
zation. The graph represents the fluorescence intensity variations observed in cells treated with 10 mM BET, 1 µM Gramicidin or Hyperpolarizing 
KRH solution. Each bar represents the mean value ± SD of three analogous experiments. Student’s t test: *p < 0.05 between fluorescence value 
recorded before and after the administration of one stimulus
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significantly (p  <  0.001) stimulated the phosphorylation 
of CaMKII isoform as measured 24 h after treatment by 
western blot analysis (Fig. 5b).
Betaine enhances SOD2 levels
Finally, we estimated BET ability to promote anti-oxida-
tive stress cellular machine. As reported in Fig. 6a, BET 
0,0
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b
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pCaMKII
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24 hours
CaMKII 24 h 
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0,0
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IF Quantification CaMKII 24 h 
*
CONTR      BET
Fig. 5 Betaine enhances CaMKII signaling pathway. a Immunofluorescence study (magnification: 40×) and relevant quantification: BET stimulated 
hObs showed a higher CaMKII positive cell number compared to control. b Representative western blot and relevant quantification: BET stimulus 
for 24 h promotes CaMKII α isoform activation. Data are the mean ± SD of six experiments performed with cells obtained from different donors. 
Student’s t test: *p ≤ 0.05, ***p ≤ 0.001
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significantly (p < 0.01) up regulated SOD2 mRNA expres-
sion after 1 h of treatment, that returned at basal values 
after 3 and 6 h. This effect was associated with a signifi-
cant increase after 6 (p < 0.01) and 24 h (p < 0.001) also 
in SOD2 protein content (Fig. 6b, c) as shown by western 
blot and immunofluorescence assay.
Discussion
In this study, we have shown that BET favours human 
osteoblast differentiation by promoting osteogenesis 
related gene expression such as RUNX2, OSX, OPN and 
BSP. Our analysis revealed that the osteogenic effect 
of BET involves the activation of calcium and ERK 
c
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Fig. 6 Betaine increases SOD2 levels. a Real time PCR. 10 mM BET up regulated significantly SOD2 gene expression after 1 h. b Western blot analysis 
and relevant quantification: BET increased significantly SOD2 protein content in hObs after 6 and 24 h treatment. c Immunofluorescence analysis 
(magnification: 40×) and relevant quantification confirmed BET positive action on SOD2 protein level. Data are the mean ± SD of six experiments 
performed with cells obtained from different donors. ANOVA for non parametric data (Kruskal–Wallis) with Dunn’s multiple comparison test: 
**p ≤ 0.01 vs control. For western blot-immunofluorescence studies: Student’s t test: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
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signaling, associated with an increased production of 
IGF-I. Calcium signaling occurred via L-type voltage-
dependent  Ca2+ channels and that it was associated with 
the depolarization of the cell membrane.
The present results are in line with our previous study 
showing that BET acts early in the process of myogen-
esis to determine cell fate [6]. We there used an in vitro 
murine model of myoblasts that, upon BET, exhibited an 
enhancement in the formation of neo myotubes, through 
the activation of IGF-I signaling. With the current study, 
we further evaluated BET role, by outlining its poten-
tial effect in human osteoblasts. Since BET up regulates 
RUNX2 and OSX gene expression and promotes the 
synthesis of specific non collagenous bone proteins, like 
BSP and OPN, it is likely that this nutrient is involved in 
triggering major events in osteogenesis and bone remod-
eling, potentially restoring the negatively affected bal-
ance of bone remodeling during aging. RUNX2 and OSX 
are indeed key transcription factors of osteoblastic dif-
ferentiation which activate the downstream processes 
of osteoblast maturation [15–19]; they also interact and 
coordinately regulate the expression of bone-specific 
genes [45]. Moreover, BSP and OPN are two non-colla-
genous proteins which serve as a matrix-associated sig-
nals presenting overlapping and multifunctional activities 
in bone with effects on bone formation, mineralization 
and remodeling [44]. Although these BET induced sig-
nals might potentially result in increased production of 
a mineralized matrix, their ultimate outcomes need to be 
experimentally assessed in vivo given their known inter-
action with local and systemic regulatory factors.
This preliminary analysis of BET effect in bone cells 
has demonstrated the involvement of ERKs activation. 
ERK pathway represents an important signaling involved 
in osteogenesis [46, 47]. In bone, ERKs promote the pro-
liferation and differentiation of osteoblasts [43, 48], and 
mediates the response of bone to a variety of stimuli, 
including hormone/growth factor stimulation [49, 50], 
extracellular matrix–integrin binding [51] and mechani-
cal loading [52]. In particular, ERK phosphorylates 
RUNX2, thus enhancing RUNX2 dependent gene expres-
sion [15–19, 46, 47, 53].
As BET was able to depolarize the osteoblast mem-
brane and to favour calcium influx by VDCCL, it is 
likely that BET could activate ERK via calcium signaling. 
In fact, it is generally acknowledged that calcium could 
activate ERK signaling via CaMKs [39, 54, 55]. Accord-
ingly, we observed CaMKII signaling activation in hObs 
treated with BET (Fig.  5). Examples of exogenous mol-
ecules able to activate a calcium influx in hOBs by the 
L-type calcium channels are already known. Melittin for 
examples, present in the honeybee, [56] and casein phos-
phopeptides, originated from the casein digestion, [30] 
behave very similar to BET. Also 1,25(OH)2 Vitamin D3 
acts on L-type calcium channels to activate the  Ca2+ cur-
rent requested to bone formation [42]. The possibility 
that food associated molecules could interact with L-type 
calcium channels and modulate the uptake of calcium by 
bone cells, can be considered as a potential tools in order 
to reach or maintain bone health.
Our study has shown that BET induces IGF-I produc-
tion in bone cells, in agreement with previous observa-
tions indicating that IGF-I is a target of BET action. Apicella 
et al. have in fact reported that BET ingestion for 2 weeks 
resulted in an increase in plasma GH and IGF-I [5]. Moreo-
ver, BET was shown to directly enhance hepatocyte IGF-I 
secretion activating ERK pathway [57]. IGF-I is crucial for 
the development and maintenance of muscle and bone mass 
[58] and for the anabolic bone actions of growth hormone 
and parathyroid hormone [9]. The stimulation of IGF-I by 
BET in both osteoblasts and myoblasts suggest a potential 
modulatory effect of BET on bone-muscle cross-talk.
Changes in IGF-I pathway, cell calcium homeostasis 
and ERK signaling are tightly linked with enhanced oxi-
dative stress and in particular with mitochondrial dys-
function [59]. Following the above consideration, our 
preliminary investigation showed that BET improves 
SOD2 gene expression and protein content, thus sug-
gesting a possible role of BET in favouring bone response 
to bone cell stress condition. Further studies will be 
required to determine specific molecular pathways medi-
ating BET effect on SOD2. This aspect is crucial in the 
hypothesis to use BET as nutraceutical supplement in 
patients with obesity or diabetes associated with osteo-
porosis and sarcopenia.
It is worth noting that primary culture of human osteo-
blast like cells is the first-line approach generally applied 
for the recognition of the potential effects of a particular 
substance on bone, as these cells are responsive to physi-
ological and pharmacological stimuli and express several 
characteristics of human osteoblasts in  vivo. Certainly, 
our in vitro findings will need further in vivo validation 
studies to better characterize the impact of BET on the 
benefit of people affected by bone and muscle mass loss.
Conclusions
The present study has demonstrated that BET exerts a 
stimulatory effect on human osteoblast by acting on syn-
ergic pathways leading to osteogenic gene activation and 
production of bone matrix proteins (Fig.  7). This study 
has a translational value in opening the perspective that 
BET supplementation, by acting on bone and muscle cells 
through common pathways, might be effective in coun-
teracting bone and muscle deterioration in the elderly, 
particularly in those individuals with an age-related pro-
inflammatory state (i.e. obese and diabetic subjects). BET 
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could represent an important nutraceutical approach in 
preventing the loss of muscle and bone with disuse, aging 
and disease, and in supporting therapies for age-related 
sarcopenia and osteoporosis [60], the major determi-
nants of senile frailty and related mortality [61].
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